Biotronik launches Lumax DX ICD trial

Biotronik has announced the start of a large-scale international trial exploring the ways its Lumax DX implantable cardioverter-defibrillator (ICD) can improve the detection and management of atrial fibrillation (AF).

The 2,000-patient Matrix study will collect device data and information on clinical events from patients implanted with the Lumax 740 or 540 VR-T DX ICDs to support the efficacy and safety of the product, while furthering understanding of the condition itself.

Lumax DX is the world's only single-chamber ICD with complete atrial diagnostics and can lowers a patient's AF-associated risks, while also avoiding the dangers associated with implantation of a second lead.

The Matrix trial will specifically examine the optimised patient management and capacity for reducing inappropriate shocks provided by the device.

Christoph Bohmer, international president for Biotronik, said: "With our DX technology, we have once again proven our drive for innovation, clinical excellence and ability to shape the future of medical device therapy."

This follows the launch of a US-based Biotronik study evaluating the safety and efficacy of its ProMRI pacing technology last week.